Chemotherapy-Induced Neutropenia (CIN) Therapeutics

Nov. 24, 2011 - PRLog -- The global Chemotherapy-induced Neutropenia (CIN) therapeutics market was worth $3.6 billion in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the expected patent expiry of Neupogen (filgrastim) n 2013 (2006 in Europe) and Neulasta (pegfilgrastim) in 2015, which will make way for the entry of biosimilars (generic version of biologics) into the market. The increase in the prescription population will help in partially offsetting the revenue loss due to patent expiries.

The current CIN therapeutics market consists of biologics such as G-CSFs such as Neupogen and Neulasta by Amgen, Gran (filgrastim) and Neu-up (nartograstim) by Kyowa Hakko Kirin Pharma, Inc. and Neutrogin/Granocyte (lenograstim) by Chugai Pharmaceuticals and GM-CSFs such as Leukine (sargramostim) by Genzyme. The market remains well-served with the current market products, most of which are significantly efficacious in their respective target areas. Essentially, the global CIN therapeutics market is heading towards a phase of continuous growth, leveraging the current opportunities.

Even though the current treatment options possess good efficacy and safety profiles, their cost of therapy is very high. The annual cost of therapy for CIN globally ranges from $5,000 to $22,000, where drugs such as Neupogen costs approximately $14,000 to $20,000 and Neulasta, the follow-on drug of Neupogen, with a better dosing regimen than its predecessor, charges an even higher premium ranging from $21,000 to $22,000. The high cost of these biologics, even though partially reimbursable, creates a significant burden on the government, as well as on the patients for the part which falls under patient copayment. Due to all the above factors the unmet need is significant in terms of cost of therapy. However, in the near future when these blockbuster drugs go off-patent, paving the way for the biosimilars, the annual cost of therapy for CIN treatment is expected to offer some relief to patients as well as governments.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The CIN developmental pipeline is primarily dominated by biosimilars, which account for approximately 80% of it. This pipeline has almost no first-in-class molecules in the clinical phases of development and this will lead to the increased dominance of biosimilars in the market after the expected patent expiry of leading biologics. In the entire pipeline, only 2% of molecules have novel mechanisms of action which are in the early stages of development and are not expected to impact the market in the forecast period. Thus, this developmental pipeline is expected to be one of the major factors that are expected to restrict the growth of the future CIN therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global CIN therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis
by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Chem...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.